FirstTake on Pharma - Pharma News and Analysis Podcast podkast

The FirstTake Podcast – The FDA faces up to a tricky ALS regulatory decision, Roche’s TIGIT setback and more…

Do tyłu o 15 sekund
Do przodu o 15 sekund
On this week’s episode Virginia Li discusses the closely watched FDA AdCom meeting for Amylyx’s ALS therapy AMX0035, which saw experts vote narrowly against Amylyx having shown sufficient efficacy for the drug from a single clinical study. Simon King looks at two major clinical data announcements – for Almirall and Eli Lilly’s atopic dermatitis drug lebrikizumab and Roche’s potential cancer therapy tiragolumab. And FirstWord HealthTech’s Tina Tan highlights some notable trends in health tech venture capitalist investments during the first quarter of 2022, ahead of an exclusive live event for FirstWord HealthTech PLUS subscribers next week where she will provide a more comprehensive overview of VC activity.

Więcej odcinków z kanału "FirstTake on Pharma - Pharma News and Analysis Podcast"